Jewish Hospital Among the First in the Country to Implement New GE Healthcare Cardiovascular Ultrasound for Procedures in the Echo Lab, OR and Cath Lab
Louisville, Ky — Jewish Hospital, part of KentuckyOne Health, today announced the implementation of GE Healthcare’s new cardiovascular ultrasound technology. Jewish Hospital is among the first centers in the country to make availablethe latest version of GE’s Vivid E9™ Breakthrough 2012 (BT12)system, introduced earlier this year. This new system includes a 4D transducer for transesophageal echocardiography (TEE) that will allow clinicians to view precise images of the heart during assessment/diagnosis performed in the echo lab, and to support invasive surgical procedures in the operating room, as well as image-guided procedures in the cath lab.
With the 4D TEE transducer, Jewish Hospital can now leverage this new technology for procedures including mitral valve repair, transcatheter aortic valve repair (TAVR/TAVI), atrial septal defect (ASD) closures and patent foraman ovale (PFO) closures. The Vivid E9 BT12 also includes several features that are new to cardiovascular ultrasound, and which are designed to enhance 4D imaging and workflow for physicians.
“At Jewish Hospital we are always striving to offer our physicians and ultimately, patients access to the latest in cutting-edge medical technology,” Valinda Rutledge, president Jewish Hospital and KentuckyOne Health Louisville market leader. “With this new Vivid E9 system, we are among the first in the country to offer the latest in 4D cardiovascular imaging, while providing our physicians workflow enhancements that could help speed up assessment and treatment times.”
Jiapeng Huang MD, PhD, a cardiothoracic anesthesiologist and director of anesthesia at Jewish Hospital used this new technology for the first time during a Transcutaneous Aortic Valve Replacement performed on an 82-year old male with severe aortic stenosis.
“The 4D TEE allowed us to accurately identify the pathology of the aortic valve, measure the aortic annulus and choose the correct size aortic valve for this patient,” said Jiapeng Huang MD, PhD. Matt Williams, M.D., with University Cardiothoracic Surgical Associates and Assistant Professor Thoracic and Cardiovascular Surgery at University of Louisville said, “As treatment for aortic valve disease becomes less invasive we rely more and more on imaging technology. The 4D TEE keeps us on the cutting edge.”
Jiapeng Huang MD, PhD also commented that 4D TEE will allow cardiac anesthesiologists, cardiac surgeons and cardiologists to inspect various cardiac structures in live 3D views. This new capacity will help physicians to define the mechanisms of mitral valve diseases, aortic valve diseases, cardiac masses, aortic diseases and congenital heart diseases. Surgical planning and repair techniques will be greatly enhanced by the ability to examine the heart from unlimited angles in 3D.
“With a recent increase in new therapeutic procedures in hospitals across the country, we at GE have been looking for ways to extend access to our ultrasound technology and help accommodate this growing need,” said Al Lojewski, General Manager of Cardiovascular Ultrasound at GE Healthcare. “Our Vivid E9 system was designed to help make 4D imaging easier and more efficient during therapeutic procedures. With the new 4D TEE transducer as well as several important workflow enhancements, this latest version of Vivid E9 underscores our commitment to making 4D ultrasound imaging accessible and efficient across the continuum of care in cardiology.”
Recently cleared by the FDA for use in the Unites States, the Vivid E9 BT12 is also CE Marked and available for sale across Europe and many countries around the world.
About Jewish Hospital
Jewish Hospital, a part of KentuckyOne Health, is an internationally renowned high-tech tertiary referral center developing leading-edge advancements in hand and microsurgery, heart and lung care, cancer care, home care, rehab medicine, sports medicine, orthopaedics, neuroscience, occupational health, organ transplantation and outpatient and primary care. Site of the world’s first successful hand transplant, the world’s first and second successful AbioCor® Implantable Replacement Heart procedures, and world’s first trial of cardiac stem cells in chronic heart failure, the hospital is in the select group that performs heart, lung, liver, kidney and pancreas transplantation.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.